It is important to continuously lower uric acid and adjust the amount to meet the standard according to the blood uric acid value. For patients who have had more than one gout attack, or who have renal insufficiency or gout stones due to the increase of uric acid, they should start continuous uric acid lowering treatment. “Many patients stop using uric acid-lowering drugs after they have no pain or normal uric acid, which is wrong because: (1) No pain only means that the inflammation is under control, but the uric acid crystals deposited in the body cannot disappear in a short time, but are quietly tripping around the joints. (2) uric acid-lowering drugs are not used to relieve pain, but to prevent future pain attacks, and only by maintaining normal uric acid for a long time can the undissolved uric acid crystals in the body be dissolved and no more attacks occur; (3) (3) The normal blood uric acid at this time is normal under the condition of medication, it does not mean that it is still normal after stopping the uric acid-lowering medication. The dose of uric acid-lowering drugs used should be adjusted according to the blood uric acid value tested every month. The key to gout treatment is to achieve the blood uric acid standard consistently (<360umol/L for those without gout stones; <300umol/L for those with gout stones), and the optimal blood uric acid value is between 200-360umol/L. If it is lower than 200umol/L, uric acid-lowering drugs can be reduced by a quarter tablet or half tablet to prevent Low uric acid induces Alzheimer's disease and Parkinson's disease, etc. (uric acid has antioxidant effect), and if it is higher than 360umol/L, uric acid-lowering drugs can be increased by a quarter tablet or half tablet. Allopurinol (inhibits uric acid synthesis), febuxostat (inhibits uric acid synthesis) and benzbromarone (promotes uric acid excretion) are all commonly used uric acid-lowering drugs and should be used according to the patient's renal function, the presence of gout stones and uric acid excretion. For those with a lot of uric acid excretion, poor renal function and existing gout stones, allopurinol or non-bustat is preferred. To prevent severe hypersensitivity syndrome, it is best to test for HLA-B*5801 gene before using allopurinol, which is prohibited in positive cases. The timing of the first addition of uric acid-lowering drugs is appropriate after the acute attack of gout has subsided, or after adequate anti-inflammatory and analgesic drugs have been given during the acute attack, but once added, gout is no longer discontinued when it reoccurs. For very high blood uric acid values, or when the efficacy of a particular uric acid-lowering drug is not good, other uric acid-lowering drugs can be switched or combined. Inhibitors of uric acid synthesis (allopurinol or febuxostat) can be combined with pro-uric acid excretory drugs (benzbromarone or propofol). During the period of uric acid lowering, acute attacks of gout often occur. Acute attacks are not ineffective, but already effective, and may be caused by the rapid or low rate of uric acid reduction. The decision to take uric acid-lowering drugs in patients with high blood uric acid who have never had an episode depends on the amount of high blood uric acid, age of onset, family history, and whether there is a combination of cardiovascular disease or cardiovascular risk factors. Uric acid-lowering therapy should be started in the following three cases: (1) in any case, the blood uric acid has exceeded 540umo/L (9mg/dl) in multiple tests; (2) the blood uric acid is 420-540umol/L (7-9mg/dl), without cardiovascular disease or cardiovascular risk factors, and after 6 months of diet control, it is still ineffective; (3) the blood uric acid is 420umol/L (7mg/dl) or more, with cardiovascular disease or cardiovascular risk factors. dl) or more, with cardiovascular disease or cardiovascular risk factors. In addition, if the patient has a family history and the age of onset is young, the addition of uric acid-lowering drugs should be active some.